FY2026 EPS Estimates for Gilead Sciences Reduced by Analyst

Key Points

• Erste Group Bank lowered its FY2026 EPS forecast for Gilead Sciences to a loss of $0.75 per share from $0.74, below the analyst consensus estimate of a $0.50-per-share loss.
• Analyst sentiment remains broadly positive, with 25 Buy ratings and four Holds, resulting in a consensus “Moderate Buy” rating and an average price target of $158.04.
• Gilead reported quarterly revenue of $7.8 billion, up 10.6% year over year and above expectations, while its $0.82 quarterly dividend implies a 2.4% annual yield.

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Equities researchers at Erste Group Bank lowered their FY2026 earnings estimates for shares of Gilead Sciences in a report issued on Wednesday, August 5th. Erste Group Bank analyst H. Engel now forecasts that the biopharmaceutical company will earn ($0.75) per share for the year, down from their prior forecast of ($0.74). The consensus estimate for Gilead Sciences' current full-year earnings is ($0.50) per share.

Several other brokerages have also recently weighed in on GILD. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $155.00 target price on shares of Gilead Sciences in a report on Wednesday, August 5th. Leerink Partners cut shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $146.00 to $127.00 in a report on Tuesday, July 21st. Wall Street Zen downgraded shares of Gilead Sciences from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Needham & Company LLC restated a "buy" rating and issued a $170.00 price objective on shares of Gilead Sciences in a report on Wednesday, August 5th. Finally, Truist Financial reduced their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a "buy" rating on the stock in a report on Tuesday, July 7th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $158.04.

Gilead Sciences Stock Performance

Shares of GILD opened at $135.77 on Wednesday. Gilead Sciences has a 1 year low of $108.46 and a 1 year high of $157.29. The stock has a market capitalization of $168.35 billion, a PE ratio of -50.85 and a beta of 0.32. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The stock has a 50-day simple moving average of $129.61 and a 200-day simple moving average of $136.39.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.Gilead Sciences's revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.01 EPS.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences's dividend payout ratio is -122.85%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares in the company, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 15,000 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the transaction, the chief executive officer directly owned 592,133 shares in the company, valued at $77,160,851.23. This trade represents a 2.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 82,000 shares of company stock worth $10,641,790 over the last three months. Insiders own 0.30% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of GILD. Strategic Investment Solutions Inc. IL purchased a new position in Gilead Sciences during the fourth quarter worth about $25,000. Persistent Asset Partners Ltd purchased a new stake in Gilead Sciences in the 2nd quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC increased its position in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 85 shares during the period. Quattro Advisors LLC acquired a new position in Gilead Sciences during the 4th quarter worth approximately $26,000. Finally, Wealth Preservation Advisors LLC raised its stake in shares of Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 81 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Strong quarterly revenue and underlying performance: Gilead’s second-quarter revenue increased roughly 10% year over year to $7.8 billion, exceeding analyst expectations. Although an $11.2 billion one-time write-off tied to acquired in-process research and development produced a reported loss, the adjusted loss of $6.75 per share was better than the $7.25 consensus estimate. GILD—An Attractive Biotech Stock with Solid Base Revenue Growth
• Positive Sentiment: Pipeline investment continues: Gilead exercised an option under its collaboration with MacroGenics to exclusively license a preclinical bispecific program. The decision triggers a $10 million payment to MacroGenics and adds another potential oncology asset to Gilead’s development portfolio, although the program remains at an early stage. MacroGenics Announces Achievement of $10 Million Milestone
• Positive Sentiment: ADC research collaboration: Gilead is working with Nucleai on AI-powered tissue analysis to support its global antibody-drug conjugate clinical programs. The collaboration could improve biomarker identification and clinical-development decisions, supporting Gilead’s oncology strategy. Nucleai Advances AI-Powered Tissue Intelligence
• Positive Sentiment: Constructive investor sentiment: A recent analysis argued that the market may be underestimating Gilead’s growth potential, while unusually heavy call-option activity indicates increased speculative interest in further gains. Gilead Sciences: The Market May Be Underestimating Its Growth
• Neutral Sentiment: Analyst questions from the earnings call focused on Gilead’s growth strategy, pipeline execution and the outlook following its latest results. Short-interest data showed no meaningful reported short position, but the figures appeared unreliable because both periods listed zero shares.
• Negative Sentiment: Erste Group Bank made a minor reduction to its fiscal 2027 earnings-per-share forecast, lowering it from $9.59 to $9.57. The small revision is a modest negative but does not materially change the earnings outlook. Gilead Sciences Analyst Estimate Update

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source